Just over one week remains to register for the PMLS Precision Diagnostics Virtual Summit. Hear from leaders from ac… 
LATEST NEWS
September 10, 2020
Bristol Myers Squibb Research at ESMO Virtual Congress 2020 Highlights Significant Progress in Cancers with High Unmet Medical Need
Bristol Myers Squibb (NYSE:BMY) today announced the presentation of research spanning 15 different cancers at the upcoming European Society for Medical Oncology (ESMO) Virtual...
Read More
September 10, 2020
AstraZeneca aims to transform cancer treatment and advance clinical practice with data presented at ESMO 2020
AstraZeneca will present new developments in pursuit of its ambition to eliminate cancer as a cause of death at the European Society for Medical...
Read More
September 10, 2020
Natera Launches Proposed Follow-On Offering
Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the launch of a proposed follow-on public offering of $250,000,000 of...
Read More
September 10, 2020
Lilly Oncology to Showcase New Data from Robust Cancer Research Pipeline at ESMO Virtual Congress 2020
Data from 20 studies across Eli Lilly and Company’s (NYSE: LLY) oncology product portfolio will be presented at the European Society for Medical Oncology...
Read More
September 10, 2020
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx)...
Read More
September 3, 2020
Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research & Development
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the appointment of...
Read More
